Skip to content

Study · Non-randomized trial · n = 45 · 2006

6 results

[Comparative analysis of efficacy of certain neuroprotectors in ischemic stroke].

Skorokhodov AP, Dudina AA, Kolesnikova EA, Koron AE, Kobantsev IuA, Sedova AA

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2006

PMID18193579 (opens in a new tab)PepBankPUB-18193579
Publisher pageAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with moderate ischemic stroke, Cerebrolysin and cortexin had similar, marked clinical effects.

    In plain wordsIn patients with moderate ischemic stroke, Cerebrolysin had a similar clinical effect to cortexin.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeClinical effect versus cortexin
    Study

    n = 45

    Comparator
    Cortexin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with moderate ischemic stroke, Cortexin and cerebrolysin showed similar clinical effects.

    In plain wordsIn patients with moderate ischemic stroke, Cortexin and cerebrolysin showed similar effects.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedClinical efficacy in moderate ischemic stroke
    Study

    n = 45

    Comparator
    cerebrolysin
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with moderate ischemic stroke, Cortexin and nootropil showed similar clinical effects.

    In plain wordsIn patients with moderate ischemic stroke, Cortexin and nootropil showed similar effects.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Direction not reportedClinical efficacy in moderate ischemic stroke
    Study

    n = 35

    Comparator
    nootropil
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.
  4. 04HumanNon-randomized trialSafety outcome

    In patients with ischemic stroke, the abstract reported an absence of side-effects with Cortexin.

    In plain wordsIn patients with ischemic stroke, the abstract reported no side effects with Cortexin.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    Not applicableSide-effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    At the same time, a domestic neuroprotector cortexin has some advantages, especially with regard to the absence of side-effects and "price-dose-therapeutic effect" criterion.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 05HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In patients with moderate ischemic stroke, the tested drugs, including Cerebrolysin, had stronger clinical effects than treatment without these drugs.

    In plain wordsIn patients with moderate ischemic stroke, the tested drugs, including Cerebrolysin, had stronger clinical effects than treatment without these drugs.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseClinical effect versus treatment without neuroprotectors
    Study

    n: not reported in source

    Comparator
    Treatment without these drugs
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 06HumanNot a test of Cortexin (cortical polypeptide complex) aloneNon-randomized trialEfficacy outcome

    In moderate ischemic stroke, the studied neuroprotectors showed stronger clinical effects than treatment without them, without a separate Cortexin estimate.

    In plain wordsIn moderate ischemic stroke, the studied drugs showed greater effects than treatment without them. Cortexin had no separate estimate.

    Peptide
    Cortexin (cortical polypeptide complex)
    Outcome
    IncreaseClinical efficacy versus treatment without neuroprotectors
    Study

    n: not reported in source

    Comparator
    treatment without these drugs
    Outcome group
    Neuroprotection · Nervous system and cognition

    Source sentences

    Summary
    The data obtained suggest that in patients with moderate IS the drugs exert a similar and rather marked effect which was stronger comparing to the treatment without these drugs.
    2 context sentences
    Summary · context
    Clinical efficacy of cortexin and nootropil has been compared in 2 therapeutic series in 35 patients and that of cortexin and cerebrolysin--in 45 patients.
    Summary · context
    The efficacy was assessed using several clinical and psychometric scales with statistical processing of the results.

    In this study, Cortexin (cortical polypeptide complex) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cortexin (cortical polypeptide complex).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  2. Version 2

    14 Oct 2026, 05:02 UTC

    Study results updated

  3. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.